Bridge Biotherapeutics announced that it would release non-clinical data of idiopathic pulmonary fibrosis (IPF) treatment candidates BBT-301 and BBT-209 at the IPF summit 2022 to be held at Boston from Aug. 29 to Sept. 1.
According to the company, BBT-301 is a novel drug candidate which fights the disease by selectively controlling ion channels. It was developed based on the examination of potassium channel (Kca 3.1)’s overexpression in IPF patients.
Bridge Bio plans to introduce non-clinical trial research data at the IPF 2022 in a poster format as it has conducted diverse non-clinical trial research after optionally adopting the project from Cellion Biomed in March.
Noteworthy data among the experiment results are lung function index from pulmonary fibrosis animal models and pathological improvement index of collagen deposition results, a major biomarker of IPF.
The company said BBT-209 is an innovative drug candidate with a mechanism for restraining fibrosis diseases through an activation of G-protein coupled receptor (GPCR19), adopted by Shaperon in April.
It will be the first time for Bridge Biotherapeutics to disclose BBT-209 data compared with a competing drug based on the analytic results of ‘α-smooth muscle actin,’ a fibroblast biomarker activated in IPF and a pathological improvement index comparison from animal models with the disease.
Last month, Bridge Bio received FDA approval to conduct a phase 2 study of BBT-877.
“We have decided to disclose non-clinical data at the IPF summit as there are increasing interests of our company’s new pipeline due to the U.S. FDA’s approval for BBT-877 phase 2 clinical trial.” said Bridge Biotherapeutics CEO Lee Jung-kue.
“We will do our best to provide new treatment options for IPF with still high unmet medical need.”